Navigation Links
Sequential and alternating chemotherapy and radiation equally effective in larynx cancer therapy
Date:1/27/2009

Larynx cancer patients treated with alternating cycles of chemotherapy and radiation have similar outcomes to patients treated with chemotherapy followed by radiation, according to data from a randomized controlled trial in the January 27 online issue of the Journal of the National Cancer Institute.

Previous trials in patients with locally advanced larynx cancer showed that chemotherapy followed by radiation was as effective as total removal of the larynx, known as laryngectomy, in terms of overall and disease-free survival and that this sequential therapy provided better quality of life. Subsequent trials indicated that concurrent administration of chemotherapy and radiation resulted in a statistically significant improvement in larynx preservation but was associated with more serious acute toxicity and possibly long term side effects.

To try to improve patient survival without increasing side effects, Jean Lefebvre, M.D., of the Centre Oscar Lambret in Lille, France, and colleagues in the European Organization for Research and Treatment of Cancer enrolled 450 patients with larynx or hypopharynx cancer in a randomized controlled trial. Patients received either chemotherapy followed by radiation or alternating cycles of radiation and chemotherapy.

With a median follow-up of 6.5 years, there was no significant difference in clinical outcomes between the two treatment groups. Larynx preservation, overall survival, and progression-free survival were similar for patients treated with sequential and alternating chemotherapy and radiation.

"The aim of our trial was to identify a regimen that would mimic concomitant chemotherapy and radiotherapy without its increased toxic effects," the authors write. "Although we achieved the latter goalefficacy was not improved." Given the results of this and several other recently-completed trials, the authors conclude that an optimal approach for larynx-preserving therapy has not been identified.

In an accompanying editorial, Arlene Forastiere, M.D., and Andy Trotti, M.D., of the Sidney Kimmel Cancer Center at Johns Hopkins University in Baltimore and the H. Lee Moffitt Cancer Center at the University of South Florida in Tampa, respectively, concur with that conclusion. The editorialists put the newly-reported data into context, reviewing other trials in the field. They note, however, that because the field currently lacks shared definitions and endpoints, synthesis of data from all the trials is difficult.

"In summary, the [current] trial showed no advantage for alternating chemotherapy and radiotherapy over traditional cisplatin plus 5-fluorouracil induction chemotherapy in hypopharynx cancer," the editorialists write. "More effective and less toxic approaches are needed. This trial also illustrates the need for common definitions and metrics to facilitate interpretation and to compare results across trials."


'/>"/>

Contact: Caroline McNeil
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Alternating mammography and MRI may be best for high-risk women
2. How chemotherapy drugs block blood vessel growth, slow cancer spread
3. UNC study supports role of circadian clock in response to chemotherapy
4. Gene Governs Response to Leukemia Chemotherapy
5. Intense chemotherapy wards off recurrence in half of mantle cell lymphoma patients after seven years
6. Oncologists Rank Aloxis Marketing Message Most Influential in the Chemotherapy-Induced Nausea and Vomiting Drug Market
7. Studies show novel device may enhance chemotherapy treatment in brain tumors
8. Iressa as Good as Chemotherapy for Lung Cancer
9. Chemotherapy plus targeted therapies shows improved survival in advance-stage lung cancer patients
10. The Neuropathy Associations Scientific Research Grants Focus: Autoimmune and Chemotherapy-Induced Neuropathies
11. SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... NEW ORLEANS (PRWEB) , ... February 11, 2016 , ... ... : Achieving Satisfaction through a Well Managed Mind” (published by Balboa Press) teaches readers ... unique way of being through profound love, author Janice McDermott, M.Ed., LCSW, offers an ...
(Date:2/11/2016)... ... February 11, 2016 , ... Student-doctors from Western University of ... Program Tuesday, February 9, taking one of the final steps in their medical ... positions across the country. Of the 103 student-doctors who comprise the College of ...
(Date:2/11/2016)... ... 2016 , ... Florida Hospital presents Heart Health Awareness night on Sunday February ... the Amalie Arena. The puck drops at 6:00pm, but fans will have the opportunity ... to the game. The MEGA Heart will be located on Ford Thunder Alley and ...
(Date:2/11/2016)... Alexandria, Va. (PRWEB) , ... February 11, 2016 , ... ... for the DoD Military Health System but would shift more of the cost burden ... described the TRICARE-reform plan laid out in the defense budget as including limited quantifiable ...
(Date:2/11/2016)... ... February 11, 2016 , ... Pediatric cardiovascular surgeons, cardiologists ... by making data on heart procedures public and easily understandable for families and ... Reporting of Pediatric and Congenital Heart Disease Outcomes will bring hundreds of pediatric ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Korea , Feb. 11, 2016 Wearable posture tracker, ALEX , has taken Kickstarter ... funded and just seven days left to go, ALEX is said to be delivered to backers starting ... ... ... Created ...
(Date:2/11/2016)... INDIANAPOLIS , Feb. 11, 2016  Attending ... but for those with type 1 diabetes, the journey ... juggle class schedules, assignments and campus activities, they also ... diabetes. On top of that, many are living away ... Scholars Foundation (Foundation) Lilly Diabetes Tomorrow,s Leaders Scholarship ...
(Date:2/11/2016)... 11, 2016  AbbVie, a global biopharmaceutical company, ... designed to provide financial support for exceptional students ... higher education goals. Fifteen scholars will be selected ... year. The AbbVie Rheumatology Scholarship is currently accepting ... president, corporate social responsibility, brand and communications, AbbVie. ...
Breaking Medicine Technology: